Extending Omalizumab Treatment Intervals in Patients with Chronic Spontaneous Urticaria

Last updated: October 14, 2024
Sponsor: Simon Francis Thomsen
Overall Status: Active - Recruiting

Phase

4

Condition

Urticaria

Hives (Urticaria)

Treatment

omalizumab 300 mg every six weeks

omalizumab 300 mg every four weeks

Clinical Study ID

NCT05916937
p-2023-14337
  • Ages > 18
  • All Genders

Study Summary

This study is a multicentre, randomized, open-label, non-inferiority clinical trial.

The purpose and aim of this study is to investigate if patients with well controlled (UCT score score ≥ 12) chronic spontaneous urticaria (CSU) on omalizumab 300 mg every four weeks can extend treatment intervals and maintain disease control.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • A diagnosis of CSU according to the EAACI/GA2LEN/EDF/WAO guidelines.

  • Age ≥ 18 years.

  • Omalizumab-naïve prior to initiating treatment with omalizumab.

  • Background treatment with four antihistamines daily.

  • Candidate for omalizumab treatment according to Danish guidelines.

Exclusion

Exclusion Criteria:

  • Pregnant or breastfeeding women.

  • Planned pregnancy within the next 6 months.

  • Weight ≥ 100 kilograms.

  • Presence of any other active skin disease or condition that may interfere with theassessment of CSU, such as atopic dermatitis, bullous pemphigoid, senile pruritus,or psoriasis.

  • Use of immunosuppressive drugs, such as prednisolone, azathioprine, methotrexate, orcyclosporine.

  • Predominantly experience symptoms from chronic inducible urticaria (CIndU).

  • Inability to complete study or comply with study procedures.

Patients with a positive basophil histamine release assay (BHRA) are not eligible for the study. Patients may therefore be withdrawn from the trial after enrolment, if they are found to have a positive BHRA test in the initial blood work.

Study Design

Total Participants: 40
Treatment Group(s): 2
Primary Treatment: omalizumab 300 mg every six weeks
Phase: 4
Study Start date:
January 12, 2024
Estimated Completion Date:
August 01, 2025

Study Description

Newly referred patients with CSU who are well-treated (UCT score ≥ 12) 12 weeks after initiating standard treatment with omalizumab 300 mg every four weeks, are randomized into two treatment arms.The first arm will continue standard treatment with omalizumab 300 mg every four weeks for 24 weeks. The second arm will receive treatment in an extended interval of omalizumab 300 mg every six weeks for 24 weeks.

Connect with a study center

  • Department of Dermatology, Bispebjerg Hospital

    Copenhagen, Copenhagen N 2100
    Denmark

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.